Nasal drug spray testing gives sponsors in vitro performance data to select pumps, compare formulations, document change control, and support submission packages. USP <601>, FDA nasal spray guidance, and ICH Q1A provide the core measurement framework for droplet size, spray geometry, dose output, breathing-interface behavior, and stability trending. Testing can include:
- PSD by laser diffraction, APS, or NGI compares nasal spray droplet and aerodynamic profiles under USP <601> and FDA nasal guidance.
- Spray pattern and plume geometry document actuator, nozzle, pump, or formulation changes for FDA comparability and change-control packages.
- Delivered dose and emitted dose series quantify actuation variability, priming, and container-life effects under USP <601>.
- Breathing simulation estimates inhaled or beyond-nose fraction using nasal fixtures, interface geometry, and FDA use-condition framing.
- Stability pulls track PSD, plume, dose, assay, and device behavior after ICH Q1A temperature and RH conditioning.
Use nasal spray testing when device output, formulation state, actuation settings, or storage history could change delivered performance. Before samples arrive, the protocol links fixture geometry, actuation sequence, particle measurement, analytical recovery, and acceptance logic. USP <1601> applies to pulmonary products for nebulization; it is not the general method reference for this device category.